Boston Common Asset Management’s Amgen AMGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$4.96M Sell
13,698
-15,942
-54% -$5.46M 0.29% 92
2026
Q1
$10.4M Sell
29,640
-3,458
-10% -$1.23M 0.67% 46
2025
Q4
$10.8M Sell
33,098
-13,018
-28% -$4.13M 0.65% 47
2025
Q3
$13M Sell
46,116
-1,344
-3% -$390K 0.36% 98
2025
Q2
$13.3M Sell
47,460
-2,255
-5% -$639K 0.37% 100
2025
Q1
$15.5M Buy
49,715
+28,004
+129% +$8.27M 0.47% 78
2024
Q4
$5.66M Buy
21,711
+21,024
+3,060% +$6.24M 0.16% 164
2024
Q3
$221K Hold
687
0.01% 305
2024
Q2
$215K Sell
687
-13,531
-95% -$3.98M 0.01% 307
2024
Q1
$4.04M Sell
14,218
-14,728
-51% -$4.31M 0.1% 220
2023
Q4
$8.34M Sell
28,946
-17,666
-38% -$4.81M 0.19% 153
2023
Q3
$12.5M Sell
46,612
-16,140
-26% -$4.03M 0.3% 120
2023
Q2
$13.9M Sell
62,752
-17,193
-22% -$3.99M 0.3% 123
2023
Q1
$19.3M Sell
79,945
-2,785
-3% -$684K 0.4% 94
2022
Q4
$21.7M Sell
82,730
-16,244
-16% -$4.35M 1.04% 29
2022
Q3
$22.3M Buy
98,974
+5,332
+6% +$1.29M 1.17% 25
2022
Q2
$22.8M Buy
93,642
+18,810
+25% +$4.61M 1.14% 26
2022
Q1
$18.1M Buy
74,832
+21,883
+41% +$5.03M 0.78% 46
2021
Q4
$11.9M Buy
52,949
+981
+2% +$207K 0.48% 68
2021
Q3
$11.1M Buy
51,968
+278
+0.5% +$64K 0.48% 72
2021
Q2
$12.6M Sell
51,690
-2,112
-4% -$520K 0.54% 63
2021
Q1
$13.4M Sell
53,802
-622
-1% -$148K 0.84% 38
2020
Q4
$12.5M Buy
54,424
+14,071
+35% +$3.24M 0.87% 37
2020
Q3
$10.3M Buy
40,353
+4,776
+13% +$1.18M 0.97% 27
2020
Q2
$8.39M Buy
35,577
+1,467
+4% +$335K 0.9% 39
2020
Q1
$6.92M Buy
34,110
+269
+0.8% +$58.8K 0.98% 28
2019
Q4
$8.16M Sell
33,841
-141
-0.4% -$31.1K 0.95% 30
2019
Q3
$6.58M Buy
33,982
+23,663
+229% +$4.54M 0.81% 50
2019
Q2
$1.9M Sell
10,319
-485
-4% -$86.8K 0.24% 89
2019
Q1
$2.05M Sell
10,804
-185
-2% -$35.3K 0.27% 89
2018
Q4
$2.14M Sell
10,989
-45
-0.4% -$8.78K 0.31% 85
2018
Q3
$2.29M Sell
11,034
-2,836
-20% -$559K 0.28% 84
2018
Q2
$2.56M Buy
13,870
+2,365
+21% +$418K 0.32% 82
2018
Q1
$1.96M Buy
+11,505
New +$2.11M 0.23% 88
2016
Q4
Sell
-4,262
Closed -$711K 189
2016
Q3
$711K Sell
4,262
-693
-14% -$117K 0.04% 224
2016
Q2
$754K Buy
4,955
+535
+12% +$83.2K 0.04% 206
2016
Q1
$663K Buy
+4,420
New +$657K 0.04% 221
2015
Q2
Sell
-2,245
Closed -$359K 275
2015
Q1
$359K Sell
2,245
-75
-3% -$11.8K 0.02% 252
2014
Q4
$370K Sell
2,320
-1,685
-42% -$263K 0.02% 250
2014
Q3
$563K Sell
4,005
-90
-2% -$11.8K 0.03% 230
2014
Q2
$485K Sell
4,095
-530
-11% -$61.4K 0.03% 231
2014
Q1
$570K Sell
4,625
-80
-2% -$9.7K 0.03% 229
2013
Q4
$537K Buy
4,705
+134
+3% +$15.2K 0.03% 230
2013
Q3
$512K Sell
4,571
-145
-3% -$15.7K 0.03% 238
2013
Q2
$465K Buy
+4,716
New +$489K 0.03% 241

Other funds holding AMGN

Boston Common Asset Management's AMGN Position: Q2 2026 in Review

Boston Common Asset Management reduced its Amgen (AMGN) stake by 54% in Q2 2026, selling an estimated $5.46M and leaving 13,698 shares worth $4.96M. The position accounts for 0.29% of the portfolio, ranked #92.

Boston Common Asset Management first reported a position in AMGN in Q2 2013 and has held it in 45 quarters since. The position peaked at $22.8M in Q2 2022. 1,244 funds tracked by Wall St. Rank hold AMGN as of Q2 2026.

  • Boston Common Asset Management held 13,698 shares of Amgen worth $4.96M as of Q2 2026.
  • Boston Common Asset Management sold 15,942 Amgen shares in Q2 2026, an estimated $5.46M.
  • Amgen made up 0.29% of Boston Common Asset Management's portfolio in Q2 2026, its #92 holding.
  • Boston Common Asset Management first reported a position in Amgen in Q2 2013 and has held it in 45 quarters since.
  • Boston Common Asset Management's Amgen position peaked at $22.8M in Q2 2022.
  • 1,244 funds tracked by Wall St. Rank held Amgen as of Q2 2026.

Based on Boston Common Asset Management's 13F filing for Q2 2026, filed 21 Jul 2026.